Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

This publication has 24 references indexed in Scilit:

• Thrombophilia and pregnancy complications
  American Journal of Obstetrics and Gynecology, 2004
• Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
  International Journal of Obesity, 2004
• Metformin, pre‐eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
  Diabetic Medicine, 2004
• Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study
  Human Reproduction, 2004
• Should we continue or stop insulin sensitizing drugs during pregnancy?
  Current Opinion in Obstetrics and Gynecology, 2004
• Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy
  Human Reproduction, 2004
• Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?
  Reproductive BioMedicine Online, 2004
• Metformin, but not Thiazolidinediones, Inhibits Plasminogen Activator Inhibitor-1 Production in Human Adipose Tissuein Vitro
  Hormone and Metabolic Research, 2003
• Polycystic ovaries and recurrent miscarriage—a reappraisal
  Human Reproduction, 2000
• Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos.
  The Journal of cell biology, 1989